Advancements in research, treatment and diagnosis have greatly improved care and outcomes for cancer patients, advocates said ...

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today unveiled its upcoming contributions ...

Outcomes4Me Inc., the developer of the leading direct-to-patient, AI-driven platform transforming the cancer care experience, today announced the close of ...

Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global ...

From trial phases to personalized care, here’s how healthcare providers can navigate cancer clinical trials and guide ...

Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Developed over five phases, BioMed Realty’s Gateway of Pacific campus consists of 2.2 million square feet of state-of-the-art ...

Part of a new £41.5 million development, the cancer centre's construction is set to be completed in 2026, despite only ...

The Royal Marsden NHS Foundation Trust, a specialist cancer center, has announced a pioneering partnership with NTT Data and CARPL.ai, a enterprise imaging artificial intelligence (AI) and machine ...

Dr Petros Grivas previews data from the AMPLITUDE trial, IRONMAN registry, genomic testing trends, emerging bispecific antibodies, and advances in radioligand therapy.

Over the past decade, immunotherapy has revolutionized cancer treatment, improving the chance for cure and survival even for poor-prognosis tumors. Immune ...